Every article, presentation, spotlight, and news item we've tagged to Metabolic Pathways.
Showing 1–24 of 77
SIRT6, a sirtuin protein, protects against neurodegenerative diseases by maintaining nucleolar function and constraining protein synthesis, preventing the accumulation of misfolded proteins that drives age-related brain pathology. This mechanism represents a direct intervention point in proteostasis failure, a primary driver of cognitive decline.
PGC-1α, a transcriptional coactivator that regulates cellular energy metabolism and mitochondrial biogenesis, is emerging as a target for age-related disease intervention. Endurance Bio is advancing a small molecule (T-168) designed to upregulate PGC-1α, with Phase 2 trials underway in Parkinson's disease and potential applications across neurodegeneration, metabolic dysfunction, and frailty.
SIRT6 maintains proteostasis by suppressing ribosomal gene expression and translation rates through nucleolar control. Without functional SIRT6, excessive protein synthesis overwhelms the folding machinery, leading to protein aggregation and accelerated neurodegeneration in aging models.
Suppressing the ghrelin receptor (GHSR-1a) improves muscle function and reduces sarcopenia in aging mice through enhanced mitochondrial efficiency and altered muscle fiber composition. Pharmacological inhibition of this receptor produced similar benefits in older mice, suggesting a translatable approach to sarcopenia without extending lifespan.
Blocking the ghrelin receptor improves muscle endurance and mitochondrial function in aging mice without affecting muscle mass or lifespan. Both genetic deletion and pharmacological inhibition restore markers of mitochondrial renewal, suggesting this pathway is a viable therapeutic target for age-related muscle decline.
Inhibiting the ghrelin receptor (GHSR-1a) improves muscle strength, exercise capacity, and mitochondrial function in aging mice, reducing sarcopenia markers without extending lifespan. Pharmacological inhibition via PF-5190457 replicates these effects and represents a translatable therapeutic approach.
Genflow Biosciences published a patent application for sirtuin 6 variants designed to prevent and treat muscle-mass loss, frailty, and sarcopenia through gene therapy. This approach targets a fundamental mechanism of age-related decline by restoring a protein variant associated with extended lifespan.
Polyamine metabolism dysregulation emerges as a mechanistic contributor to postoperative delirium, with specific metabolites showing potential as predictive biomarkers. This work identifies a biochemical pathway relevant to acute cognitive dysfunction in aging populations and surgical contexts, offering a measurable entry point for intervention.
Pck1 enzyme depletion in adipose tissue accelerates cellular senescence and metabolic dysfunction, linking metabolic enzyme loss to accelerated aging in fat cells. This identifies a specific enzymatic mechanism by which declining metabolic capacity in aging tissue drives the accumulation of senescent cells and their inflammatory consequences.
Exercise triggers release of exosome-delivered eNAMPT, which activates hepatic SIRT1 and autophagy to reverse age-related fatty liver disease, inflammation, and fibrosis in aged mice. This mechanism establishes a biochemical pathway through which physical activity protects metabolic health during aging.
Zfp462 is a transcriptional regulator essential for osteoblast differentiation and bone formation; aging reduces its expression through altered histone occupancy at its locus, providing a mechanistic explanation for age-related bone loss. Restoring Zfp462 activity or its associated transcriptional machinery represents a potential intervention pathway for senile osteoporosis.
HDAC9 gene deletion in mice reduces age-related fat tissue senescence and restores mitochondrial function through upregulation of thiosulfate sulfurtransferase (TST), a protein whose decline contributes to metabolic dysfunction during aging. This identifies HDAC9 as a druggable epigenetic target for preserving adipose tissue health.
Suppressing growth hormone signaling in adipose tissue of aged mice preserved cognitive function, reduced neuroinflammation and cellular senescence, and restored neural firing patterns to near-youthful levels. This demonstrates adipose tissue as a peripheral regulator of brain aging independent of systemic growth hormone levels.
Atrogi has initiated human trials of ATR-258, an oral drug designed to preserve muscle mass during weight loss by mimicking exercise-induced metabolic effects. The approach addresses a critical gap in current obesity therapeutics: preventing muscle loss alongside fat loss, which is essential for maintaining strength, resilience, and functional independence in aging.
Physical exercise elevates circulating adiponectin, which activates PP2A phosphatase in the hippocampus to reduce pathological tau phosphorylation and restore cognitive function under chronic stress. This mechanism operates independently of adiponectin's other metabolic functions and identifies a direct molecular pathway by which exercise protects against Alzheimer's-like neuropathology.
TOS-358, a selective mTOR complex 1 inhibitor, demonstrated a 50% clinical benefit rate and 75% disease control rate in Phase 1a testing, with a notably favorable safety profile compared to existing PI3K/AKT/mTOR pathway inhibitors. The compound showed efficacy in patients resistant or intolerant to standard therapies in this class, positioning it as a potential therapeutic option for advanced malignancies.
A correction to prior research on photobiomodulation's mechanism in Alzheimer's disease clarifies the molecular pathway by which light exposure modulates neuroinflammatory signaling. The finding reinforces the relevance of non-pharmacological interventions targeting neurodegeneration at the cellular level.
Dietary restriction demonstrates geroprotective effects across species through multiple molecular pathways, though human data remains inconsistent and mechanistic understanding incomplete. This class of intervention represents a critical reference point for evaluating longevity strategies, particularly in identifying which downstream mechanisms drive aging resistance versus which reflect caloric reduction alone.
Mimio Health's fasting-mimetic therapy produced biomarker changes consistent with fasting physiology—including improved metabolic markers and enhanced fat metabolism—without dietary modification. The intervention was well tolerated and represents a pharmacological approach to accessing metabolic benefits traditionally associated with caloric restriction.
A randomized controlled trial of a fasting mimetic formulation in overweight older adults with elevated HbA1c showed reductions in LDL particle number, oxidized LDL, and fasting glucose over eight weeks. The compound—a blend of spermidine, nicotinamide, palmitoylethanolamide, and oleoylethanolamide—reproduced several cardiometabolic signatures associated with fasting without dietary restriction, though durability beyond the study period remains undemonstrated.
A combination of NMN and apigenin preserves NAD+ levels, activating SIRT3 to suppress cellular senescence and promote differentiation of muscle, bone, and cartilage precursor cells. The regimen also modulates the gut microbiota to increase production of phytosphingosine, an anti-aging metabolite, resulting in improved musculoskeletal function and exercise capacity in aged animals.
NAD+ preservation through dual mechanisms—inhibiting its depletion and enhancing its synthesis—delays cellular senescence while promoting musculoskeletal regeneration. This addresses a central constraint in aging: the body's declining capacity to maintain energy production and tissue repair as NAD+ levels fall with time.
Low-dose rapamycin protects DNA in aging immune cells by reducing damage-induced cell death and senescence markers, suggesting mTOR inhibition preserves immune resilience through direct genoprotection rather than broad immunosuppression. This mechanistic clarity offers a more tractable regulatory and therapeutic pathway than the traditional anti-aging framing.
A correction to a study examining how ad libitum feeding can extend lifespan through mechanisms opposite to caloric restriction, particularly involving energy-splicing pathways. This finding challenges the assumption that caloric restriction is the only dietary approach to lifespan extension and suggests multiple metabolic routes can achieve similar longevity outcomes.
